Please assess the completion status of the following clinical trial:

Trial Title: A Study of IMP4297 in Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed Informed Consent Form~2. 18 Years to 70 Years (including 18 and 75 years)~3. Histologically or cytologically documented disease; incurable, advanced solid malignancy that has progressed on, or failed to respond to, at least one prior systemic therapy~4. Eastern Cooperative Oncology Group performance status of 0 or 1~5. In the dose expansion stage, patients with BRCA (breast carcinoma) mutation will be enrolled. Patients with breast cancer, ovarian cancer and prostate cancer are preferred.~6. In the dose escalation phase, at least one assessable lesion according to the RECIST 1.1 standard; In the dose expansion phase, at least one measurable lesion according to RECIST 1.1.~Exclusion Criteria:~1. Inadequate hematologic and organ function, defined by the following (hematologic parameters must be assessed ≥14 days after a prior treatment, if any):~   1. Absolute neutrophil count \<1500 cells/µL~  2. Hemoglobin \< 9 g/dL~  3. Total bilirubin \> 1.5 × the upper limit of normal (ULN), with documented liver metastases total bilirubin \> 3 × the ULN.~  4. Aspartate transaminase (AST) and/or alanine transaminase (ALT) \> 2.5 × the ULN, with documented liver metastases AST and/or ALT levels \> 5 × the ULN.~  5. Serum creatinine \> 1.5 × the ULN, or creatinine clearance \< 45 mL/min based on a documented 24-hour urine collection or Cockcroft-Gault calculation of glomerular filtration rate.~  6. International normalized ratio (INR) \> 1.5 × the ULN or activated partial thromboplastin time (aPTT) \> 1.5 × the ULN.~   The INR applies only to patients who do not receive therapeutic anti-coagulation.~2. Any anti-cancer therapy, including chemotherapy, hormonal therapy, biologic therapy, radiotherapy within 4 weeks prior to initiation of study treatment with the following exceptions:~   1. Hormonal therapy with gonadotropin-releasing hormone (GnRH) agonists for prostate cancer.~  2. Hormone-replacement therapy or oral contraceptives.~  3. Palliative radiation to bone metastases \> 2 weeks prior to Day 1.~3. Adverse events from prior anti-cancer therapy that have not resolved to NCI CTCAE Grade ≤ 1, except for alopecia.~4. Prior therapies targeting PARP (poly-ADP ribose polymerase).~5. Clinical significant active infection~6. Known clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis~7. Known human immunodeficiency virus infection~8. New York Heart Association Class II or greater congestive heart failure; history of myocardial infarction or unstable angina within 6 months prior to Day 1; history of stroke or transient ischemic attack within 6 months prior to Day 1~9. Active or untreated brain metastasis~10. Pregnant (positive pregnancy test) or lactating women~11. Male or female patients of child-producing potential unwilling to use double barrier contraception: condoms, sponge, foams, jellies, diaphragm or intrauterine device, contraceptives (oral, injectable or parenteral), implanon, or other avoidance of pregnancy measures during the study and for 90 days after the last day of treatment~12. Inability to take oral medication, prior surgical procedures affecting absorption, or active peptic ulcer disease~13. Inability to comply with study and follow-up procedures~14. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patient at high risk from treatment complications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- IMP4297 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).